文献速递慢性肾脏病血液净化与透析

莫利司他在慢性肾脏病贫血治疗中的效果

Effects of Molidustat in the Treatment of Anemia in CKD.
PubMed 文献 · Clin J Am Soc Nephrol · 2018-12-17

三项为期16周的2b期研究评估了低氧诱导因子-脯氨酰羟化酶抑制剂莫利司他治疗慢性肾脏病贫血的疗效与安全性。DIALOGUE 1为安慰剂对照固定剂量试验(n=121),DIALOGUE 2和4为开放标签可变剂量试验(n=124和n=199),分别与达依泊汀或依泊汀转换治疗比较。莫利司他总体耐受性良好,不良事件多为轻中度,支持其进入3期开发。

要点

  • 莫利司他可升高未透析CKD贫血患者血红蛋白1.4-2.0 g/dl。
  • 透析患者从依泊汀转换为莫利司他后血红蛋白维持在目标范围。
  • 莫利司他总体耐受性良好,多数不良事件为轻中度。

核心结论

  • 莫利司他在CKD贫血患者中2期疗效和安全性总体良好,支持推进3期开发。

研究设计与样本

  • 三项16周2b期研究:DIALOGUE 1为安慰剂对照固定剂量试验(n=121),DIALOGUE 2(n=124)和4(n=199)为开放标签可变剂量试验。
  • DIALOGUE 1剂量为25、50、75 mg每日一次或25、50 mg每日两次;DIALOGUE 2起始25-75 mg每日,DIALOGUE 4起始25-150 mg每日,可滴定维持血红蛋白目标范围。
  • 主要终点为基线至治疗期最后4周平均血红蛋白的变化。

主要发现

  • DIALOGUE 1中莫利司他治疗估计使平均血红蛋白升高1.4-2.0 g/dl。
  • DIALOGUE 2中转换为莫利司他后血红蛋白维持在目标范围,与达依泊汀相比平均变化估计差异最高0.6 g/dl。
  • DIALOGUE 4中转换为莫利司他75和150 mg后血红蛋白维持在目标范围,与依泊汀相比平均变化估计差异分别为-0.1和0.4 g/dl。
  • 莫利司他总体耐受性良好,大多数不良事件为轻中度。

临床怎么用

  • 莫利司他可用于未透析或透析CKD贫血患者升高或维持血红蛋白。
  • 从促红细胞生成素刺激剂转换为莫利司他时需滴定剂量以维持血红蛋白目标范围。

局限性

  • 研究为2b期,样本量有限,长期安全性和心血管结局未评估。
  • DIALOGUE 2和4为开放标签设计,可能存在偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: The efficacy and safety of molidustat, a hypoxia-inducible factor-prolyl hydroxylase inhibitor, have been evaluated in three 16-week, phase 2b studies in patients with CKD and anemia who are not on dialysis (DaIly orAL treatment increasing endOGenoUs Erythropoietin [DIALOGUE] 1 and 2) and in those who are on dialysis (DIALOGUE 4). DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: DIALOGUE 1 was a placebo-controlled, fixed-dose trial (25, 50, and 75 mg once daily; 25 and 50 mg twice daily). DIALOGUE 2 and 4 were open-label, variable-dose trials, in which treatment was switched from darbepoetin (DIAGLOGUE 2) or epoetin (DIALOGUE 4) to molidustat or continued with the original agents. Starting molidustat ranged between 25-75 and 25-150 mg daily in DIAGLOGUE 2 and 4, respectively, and could be titrated to maintain hemoglobin levels within predefined target ranges. The primary end point was the change in hemoglobin level between baseline and the mean value from the last 4 weeks of the treatment period. RESULTS: In DIAGLOGUE 1 (n=121), molidustat treatment was associated with estimated increases in mean hemoglobin levels of 1.4-2.0 g/dl. In DIAGLOGUE 2 (n=124), hemoglobin levels were maintained within the target range after switching to molidustat, with an estimated difference in mean change in hemoglobin levels between molidustat and darbepoetin treatments of up to 0.6 g/dl. In DIAGLOGUE 4 (n=199), hemoglobin levels were maintained within the target range after switching to molidustat 75 and 150 mg, with estimated differences in mean change between molidustat and epoetin treatment of -0.1 and 0.4 g/dl. Molidustat was generally well tolerated, and most adverse events were mild or moderate in severity. CONCLUSIONS: The overall phase 2 efficacy and safety profile of molidustat in patients with CKD and anemia enables the progression of its development into phase 3.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Macdougall IC, Akizawa T, Berns JS, et al. Effects of Molidustat in the Treatment of Anemia in CKD. Clin J Am Soc Nephrol. 2018. PMID: 30559105. doi:10.2215/CJN.02510218

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。